Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life.
Quality of life measures have received little attention in evaluation of therapy for dyspepsia. To examine the effect of cisapride on gastrointestinal symptoms and quality of life measures, we studied eight patients with chronic, severe dyspepsia, before and after therapy with cisapride (20 mg three times daily) for 12 months. Gastrointestinal (GI) Total Symptom Score (TSS), Overall Patient Assessment (OPA), and quality of life by both trait (Minnesota Multiphasic Personality Inventory (MMPI)) and physical function (Sickness Impact Profile (SIP)) were measured at base line and at month 12 of cisapride therapy. Results showed significant improvement in TSS, OPA, and the MMPI Depression and Anxiety scales (all, p < 0.05). Improvement in the SIP physical dimension score approached significance (p = 0.065). We conclude that, in this group of patients with severe dyspepsia, both GI symptoms and quality of life measures improved with 12 months of cisapride therapy. These quality of life measures may prove useful in evaluating the efficacy of drug treatment for dyspepsia.
Dept. of Medicine (Gastroenterology Division), University of Tennessee, Memphis 38163.
T L
TL
Abell
T F
TF
Cutts
T
T
Cooper
D000328:Adult; D000368:Aged; D020117:Cisapride; D004415:Dyspepsia / Q000188:drug therapy* / Q000523:psychology*; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008950:MMPI; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D011788:Quality of Life; D012720:Severity of Illness Index
D010880:Piperidines; D020117:Cisapride